GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galapagos NV (BSP:G1LP34) » Definitions » Shiller PE Ratio

Galapagos NV (BSP:G1LP34) Shiller PE Ratio : (As of May. 20, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Galapagos NV Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Galapagos NV Shiller PE Ratio Historical Data

The historical data trend for Galapagos NV's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galapagos NV Shiller PE Ratio Chart

Galapagos NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Galapagos NV Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Galapagos NV's Shiller PE Ratio

For the Biotechnology subindustry, Galapagos NV's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Galapagos NV's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Galapagos NV's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Galapagos NV's Shiller PE Ratio falls into.



Galapagos NV Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Galapagos NV's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Galapagos NV's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=7.416/130.5518*130.5518
=7.416

Current CPI (Mar. 2024) = 130.5518.

Galapagos NV Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 0.000 99.482 0.000
201409 -1.295 99.195 -1.704
201412 -1.108 99.086 -1.460
201503 -1.598 99.423 -2.098
201506 -2.060 100.107 -2.687
201509 -3.154 100.245 -4.108
201512 -6.510 100.572 -8.451
201603 3.253 101.653 4.178
201606 -0.385 102.267 -0.491
201609 -1.935 102.118 -2.474
201612 3.432 102.614 4.366
201703 -0.970 103.972 -1.218
201706 -2.629 103.902 -3.303
201709 -2.726 104.170 -3.416
201712 -2.301 104.804 -2.866
201803 -2.952 105.419 -3.656
201806 -1.850 106.063 -2.277
201809 1.342 106.618 1.643
201812 1.325 107.252 1.613
201903 -3.862 107.876 -4.674
201906 -3.747 107.896 -4.534
201909 27.357 107.470 33.233
201912 -9.896 108.065 -11.955
202003 -4.211 108.550 -5.065
202006 -10.342 108.540 -12.439
202009 -7.951 108.441 -9.572
202012 -5.508 108.511 -6.627
202103 0.939 109.522 1.119
202106 -5.937 110.305 -7.027
202109 -6.148 111.543 -7.196
202112 1.597 114.705 1.818
202203 -1.096 118.620 -1.206
202206 -1.547 120.948 -1.670
202209 1.713 124.120 1.802
202212 -17.559 126.578 -18.110
202303 1.952 126.528 2.014
202306 0.421 125.973 0.436
202309 2.056 127.083 2.112
202312 12.770 128.292 12.995
202403 7.416 130.552 7.416

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Galapagos NV  (BSP:G1LP34) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Galapagos NV Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Galapagos NV's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Galapagos NV (BSP:G1LP34) Business Description

Address
Generaal De Wittelaan L11 A3, Mechelen, BEL, 2800
Galapagos NV is a clinical-stage biotechnology company, involved in the discovery and development of small-molecule medicines. The company's product candidate portfolio includes Filgotinib, a JAK1 inhibitor to treat rheumatoid arthritis, Crohn's disease, and ulcerative colitis; novel therapies in cystic fibrosis (a chronic disease that affects the lungs and digestive system); GLPG1690, a selective autotaxin inhibitor with potential application in idiopathic pulmonary disease; GLPG1972 to treat osteoarthritis; and MOR106 to treat atopic dermatitis.

Galapagos NV (BSP:G1LP34) Headlines

No Headlines